Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Gross Profit : NT$2.62 Mil (TTM As of Dec. 2023)

Great Novel Therapeutics Biotech & Medicals Gross Profit Chart

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Gross Profit	Get a 7-Day Free Trial					0.13	0.46	-	4.76	-2.15

Competitive Comparison of Great Novel Therapeutics Biotech & Medicals's Gross Profit

For the Biotechnology subindustry, Great Novel Therapeutics Biotech & Medicals's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Great Novel Therapeutics Biotech & Medicals's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Great Novel Therapeutics Biotech & Medicals's Gross Profit distribution charts can be found below:

* The bar in red indicates where Great Novel Therapeutics Biotech & Medicals's Gross Profit falls into.

Great Novel Therapeutics Biotech & Medicals Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Great Novel Therapeutics Biotech & Medicals's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Great Novel Therapeutics Biotech & Medicals's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$2.62 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Great Novel Therapeutics Biotech & Medicals's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Great Novel Therapeutics Biotech & Medicals  (ROCO:7427) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Great Novel Therapeutics Biotech & Medicals had a gross margin of -2,439.77% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage

Great Novel Therapeutics Biotech & Medicals Gross Profit Related Terms

Thank you for viewing the detailed overview of Great Novel Therapeutics Biotech & Medicals's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Business Description